NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

/PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel...

Related Keywords

Japan ,United States ,Japanese , ,Nanoviricides Inc ,Drug Administration ,Exchange Commission ,Committee For Medicinal Products Human ,Development To Enter Clinical Trials ,Theracour Pharma Inc ,Drug In Development ,European Medicines Agency ,Securities Exchange ,Corporate Presentation ,Benzinga Conference ,Center Clinical Trials ,Are Thus Expected ,Work Against Variants ,Increasing Resistance ,Existing Drugs ,Would Therefore Not ,Escape Our Drugs ,Unlike Existing Drugs ,Only Drug ,Dual Mode ,Attacking Cells ,Virus Replication Inside Cells ,Complete Lifecycle ,Component Blocks ,Replication Cycle Inside Cells ,Model Studies Have Indicated ,Substantially Superior ,Controlling Coronavirus Lethal Lung Infection ,Extension Over Untreated Infected Animals ,Extremely Safe ,Body Weight ,Substantial Therapeutic Margin ,Toxicology Studies ,Neurological Function Adverse Effects ,Neuro Pulmonary Model Studies ,Cardiovascular Function Adverse Effects ,Cynomolgus Monkey ,Non Human Primate ,Benzinga Healthcare Small Cap ,Benzinga Healthcare Small Cap Conference ,Small Cap ,Educational Modules ,Human Immunodeficiency Virus ,Hepatitisb Virus ,Hepatitisc Virus ,Herpes Simplex Virus ,Varicella Zoster Virus ,Asian Bird Flu Virus ,Japanese Encephalitis ,West Nile Virus ,Theracour Pharma ,Securities Act ,Securities Exchange Act ,United States Securities ,Good Manufacturing ,Medicinal Products ,Human Use ,Nanoviricides ,Nc ,